文献类型：期刊文献

英文题名：Effect of primary tumor resection on survival in patients with asymptomatic unresectable metastatic colorectal cancer: a systematic review and meta-analysis

作者：Zhang, Chengren[1,2,3];Cao, Cong[1,2,3];Liu, Lili[4];Lv, Yaochun[2,3,5];Li, Jingjing[1,2,3];Lu, Jiyong[2,3,4];Wang, Shuai[2,3,4];Du, Binbin[2,3];Yang, Xiongfei[2,3,5]

第一作者：Zhang, Chengren

通信作者：Lv, YC[1];Yang, XF[1]

机构：[1]Ningxia Med Univ, Clin Med Coll, Yinchuan, Ningxia Hui Aut, Peoples R China;[2]Gansu Prov Hosp, Dept Anorectal Surg, Lanzhou, Gansu, Peoples R China;[3]Gansu Prov Peoples Hosp, Anorectal Dis Res Ctr, Lanzhou, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Dept First Clin Med Coll, Lanzhou, Gansu, Peoples R China;[5]Gansu Prov Peoples Hosp, Dept anorectal Surg, Lanzhou 730000, Gansu, Peoples R China

第一机构：Ningxia Med Univ, Clin Med Coll, Yinchuan, Ningxia Hui Aut, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Peoples Hosp, Dept anorectal Surg, Lanzhou 730000, Gansu, Peoples R China.

年份：2023

卷号：23

期号：1

起止页码：107

外文期刊名：EXPERT REVIEW OF ANTICANCER THERAPY

收录：;Scopus(收录号：2-s2.0-85142652955);WOS:【SCI-EXPANDED(收录号:WOS:000889673600001)】；

基金：This research was supported by the Scientific Research Fund of Gansu Provincial Hospital (20GSSY3-1, 21GSSYC-20) and the Science and Technology Fund of Lanzhou City (2022-ZD-47).

语种：英文

外文关键词：Metastatic colorectal cancer; chemotherapy; primary tumor resection; meta-analysis

摘要：ObjectiveIt remains controversial whether primary tumor resection (PTR) improves survival in patients with asymptomatic, unresectable metastatic colorectal cancer (mCRC). Therefore, we conducted a meta-analysis to assess the latest evidence on clinical outcomes.Materials and MethodsWe systematically searched PubMed, Web of Science, Cochrane Library, and Embase databases for eligible studies published between database inception and May 2022. RevMan 5.4 and Stata 16.0 were used for the meta-analysis.ResultsA total of nine studies were included, including four randomized controlled trials (RCTs) and five retrospective cohort studies. Meta-analysis showed that overall survival (OS) [HR = 0.89, 95%CI (0.74, 1.06), P = 0.19] and progression-free survival (PFS) [HR = 0.87, 95%CI (0.71, 1.06), P = 0.17] were not significantly different between the PTR and non-PTR groups. In the subgroup analysis, all subgroups showed no significant difference in OS between the two groups.ConclusionPTR may not provide additional survival benefits over chemotherapy in asymptomatic, unresectable mCRC patients. However, in view of the limitations of this study, more well-designed RCTs are needed to validate our conclusions.